G-CSF: Boosting endogenous production - a new strategy?

Zitieren

Dateien zu dieser Ressource

Prüfsumme: MD5:d94e1da4e11cbe77689736839fbf400d

AULOCK, Sonja von, Isabel DITERICH, Lars HARENG, Thomas HARTUNG, 2004. G-CSF: Boosting endogenous production - a new strategy?. In: Current Opinion in Investigational Drugs. 5(11), pp. 1148-1152

@article{Aulock2004G-CSF-8109, title={G-CSF: Boosting endogenous production - a new strategy?}, year={2004}, number={11}, volume={5}, journal={Current Opinion in Investigational Drugs}, pages={1148--1152}, author={Aulock, Sonja von and Diterich, Isabel and Hareng, Lars and Hartung, Thomas} }

<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:bibo="http://purl.org/ontology/bibo/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > <rdf:Description rdf:about="https://kops.uni-konstanz.de/rdf/resource/123456789/8109"> <dc:contributor>Aulock, Sonja von</dc:contributor> <bibo:uri rdf:resource="http://kops.uni-konstanz.de/handle/123456789/8109"/> <dcterms:bibliographicCitation>First publ. in: Current Opinion in Investigational Drugs 5 (2004), 11, pp. 1148-1152</dcterms:bibliographicCitation> <dc:creator>Hartung, Thomas</dc:creator> <dc:creator>Aulock, Sonja von</dc:creator> <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2011-03-24T17:40:41Z</dcterms:available> <dc:rights>deposit-license</dc:rights> <dcterms:title>G-CSF: Boosting endogenous production - a new strategy?</dcterms:title> <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2011-03-24T17:40:41Z</dc:date> <dc:format>application/pdf</dc:format> <dc:contributor>Hareng, Lars</dc:contributor> <dcterms:rights rdf:resource="http://nbn-resolving.org/urn:nbn:de:bsz:352-20140905103416863-3868037-7"/> <dc:creator>Hareng, Lars</dc:creator> <dc:contributor>Hartung, Thomas</dc:contributor> <dc:creator>Diterich, Isabel</dc:creator> <dc:language>eng</dc:language> <dcterms:abstract xml:lang="eng">Granulocyte colony-stimulating factor (G-CSF) has been in clinical use for over a decade. Its main applications are in adjunctive medication to chemotherapy and in mobilizing stem cells for bone marrow transplantation. However. it has additional effects in that it primes neutrophilic granulocytes for improved host defense, and reduces the release of pro-inflammatory cytokines. These effects have prompted trials for numerous other indications. New research into the production and regulation of G-CSF in health and disease may now enable tailored strategies to induce or boost G-CSF formation. Similarly. new forms of application may increase its effectiveness.</dcterms:abstract> <dcterms:issued>2004</dcterms:issued> <dc:contributor>Diterich, Isabel</dc:contributor> </rdf:Description> </rdf:RDF>

Dateiabrufe seit 01.10.2014 (Informationen über die Zugriffsstatistik)

G_CSF_Boosting_endogenous_production_a_new_strategy.pdf 216

Das Dokument erscheint in:

KOPS Suche


Stöbern

Mein Benutzerkonto